C L Masters
Overview
Explore the profile of C L Masters including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
315
Citations
13461
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Souchet B, Michail A, Heuillet M, Dupuy-Gayral A, Haudebourg E, Pech C, et al.
J Prev Alzheimers Dis
. 2025 Jan;
12(2):100026.
PMID: 39863330
No abstract available.
2.
Souchet B, Michail A, Heuillet M, Dupuy-Gayral A, Haudebourg E, Pech C, et al.
J Prev Alzheimers Dis
. 2024 May;
11(3):567-581.
PMID: 38706273
Background: The primary criteria for diagnosing mild cognitive impairment (MCI) due to Alzheimer's Disease (AD) or probable mild AD dementia rely partly on cognitive assessments and the presence of amyloid...
3.
Liu H, Li J, Ziegemeier E, Adams S, McDade E, Clifford D, et al.
J Prev Alzheimers Dis
. 2024 May;
11(3):558-566.
PMID: 38706272
Background: Clinical trial satisfaction is increasingly important for future trial designs and is associated with treatment adherence and willingness to enroll in future research studies or to recommend trial participation....
4.
Feizpour A, Dore V, Doecke J, Saad Z, Triana-Baltzer G, Slemmon R, et al.
J Prev Alzheimers Dis
. 2023 Oct;
10(4):828-836.
PMID: 37874105
Background: Plasma p217+tau has shown high concordance with cerebrospinal fluid (CSF) and positron emission tomography (PET) measures of amyloid-β (Aβ) and tau in Alzheimer's Disease (AD). However, its association with...
5.
Angioni D, Hansson O, Bateman R, Rabe C, Toloue M, Braunstein J, et al.
J Prev Alzheimers Dis
. 2023 Jun;
10(3):418-425.
PMID: 37357282
In randomized clinical trials (RCTs) for Alzheimer's Disease (AD), cerebrospinal fluid (CSF) and positron emission tomography (PET) biomarkers are currently used for the detection and monitoring of AD pathological features....
6.
Vermunt L, Sutphen C, Dicks E, de Leeuw D, Allegri R, Berman S, et al.
medRxiv
. 2023 Apr;
PMID: 37016671
Key Points: Abnormal levels of fluid markers for neuronal damage and inflammatory processes in CSF are associated with grey matter network disruptions.The strongest association was with NfL, suggesting that axonal...
7.
Piccirella S, Van Neste L, Fowler C, Masters C, Fripp J, Doecke J, et al.
J Prev Alzheimers Dis
. 2022 Jul;
9(3):469-479.
PMID: 35841248
Background: Ongoing research seeks to identify blood-based biomarkers able to predict onset and progression of Alzheimer's disease (AD). Objective: The unfolded conformational variant of p53 (U-p53AZ), previously observed in AD...
8.
Walia N, Eratne D, Loi S, Li Q, Varghese S, Malpas C, et al.
J Neurol Sci
. 2021 Dec;
432:120088.
PMID: 34922179
Introduction: Determining disease severity and predicting prognosis in younger onset-dementia (YOD) remains challenging. Whether CSF biomarkers neurofilament light (NfL), tau and amyloidβ 42 (Aβ42) can help provide such information has...
9.
Lai M, Ames D, Cox K, Ellis K, Sharman M, Hepworth G, et al.
J Nutr Health Aging
. 2020 Mar;
24(3):300-304.
PMID: 32115611
Objectives: Metabolic syndrome (MetS) represents a cluster of obesity and insulin resistance-related comorbidities. Abdominal obesity, hypertension, elevated triglyceride and glucose levels are components of MetS and may have a negative...
10.
Burnham S, Coloma P, Li Q, Collins S, Savage G, Laws S, et al.
J Prev Alzheimers Dis
. 2019 Nov;
6(4):248-255.
PMID: 31686097
Background: The National Institute on Aging and Alzheimer's Association (NIA-AA) have proposed a new Research Framework: Towards a biological definition of Alzheimer's disease, which uses a three-biomarker construct: Aß-amyloid, tau...